ArticleMethods in molecular biology (Clifton, N.J.)2026
Intelligence Disclosure on Deploying SpyTag/SpyCatcher for Nanoparticle Assembly.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunization with antigens presented multivalently on virus-like particles elicits potent immune responses. The SpyTag/SpyCatcher system, which allows spontaneous covalent bond formation between two proteins, provides a simple route to functionalize virus-like particles for multivalent presentation. Termed SpyVLPs, these reactive nanoparticles allow modular plug-and-display of different antigens. SpyCatcher003-mi3 is a resilient SpyVLP that can be produced at high yield, allows efficient coupling, and can be applied to vaccines against a diverse range of pathogens, as well as against cancer and allergy. Here, we describe the procedure for the expression and purification of SpyCatcher003-mi3. We outline considerations related to antigen design, multivalent display, nanoparticle validation, and immunogen preparation that are critical for effective implementation of SpyCatcher003-mi3 and other SpyVLPs. The methods discussed are applicable beyond vaccines, extending to therapeutic targeting, diagnostics, and catalysis.
Indexed as
Identifiers
42542483What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.